DRREDDY vs LINCOLN: Stock Comparison
DR. REDDY S LABORATORIES is the larger company by market capitalisation. DR. REDDY S LABORATORIES shows a higher dividend yield and a higher ROCE, while LINCOLN PHARMA shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
DRREDDY leads 6; LINCOLN leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | DRREDDY | LINCOLN |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | DRREDDY | LINCOLN |
|---|---|---|
| Live Price | ₹1,239 | ₹510.85 |
| Day Change | -0.44% | -0.72% |
| Volume | 28.05 L | 61,149 |
| 52-Week High | ₹1,414.9 | ₹770 |
| 52-Week Low | ₹1,101 | ₹440 |
| Distance from 52W High | -12.43% | -33.66% |
Valuation
| Metric | DRREDDY | LINCOLN |
|---|---|---|
| Market Cap | ₹1.03 L Cr | ₹1,023 Cr |
| P/E Ratio | 32.09x | 10.61x |
| P/B Ratio | 2.73x | 1.35x |
| EPS | ₹39.74 | ₹18.09 |
| Book Value | ₹460.31 | ₹378.25 |
| Dividend Yield | 0.64% | 0.35% |
Growth
| Metric | DRREDDY | LINCOLN |
|---|---|---|
| Revenue Growth (TTM YoY) | -11.6% | 11.4% |
| EPS Growth (TTM YoY) | -86.2% | 0.6% |
| Qtr Sales Growth | 7.33% | 0% |
| Qtr Profit Growth | 96.84% | 0% |
Profitability & Leverage
| Metric | DRREDDY | LINCOLN |
|---|---|---|
| ROE | 10.27% | 11.6% |
| ROCE | 12.07% | 10.97% |
| Net Margin | 12.76% | 13.1% |
| Operating Margin | 21.43% | 17.38% |
| Debt to Equity | 0.17x | 0.01x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | DRREDDY | LINCOLN |
|---|---|---|
| Promoter Holding | 26.64%▲ 0.01 pp | 49.78% |
| FII Holding | 32.07%▼ 1.01 pp | 4.6%▼ 0.59 pp |
| DII Holding | 31.74%▲ 1.02 pp | 0.27%▼ 0.82 pp |
| Public Holding | 9.35%▲ 0.02 pp | 45.36%▲ 1.42 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: DR. REDDY S LABORATORIES and LINCOLN PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.